P2RY12 and Arterial thrombosis: Although P2Y12 inhibitors have been shown to be able modulate inflammatory pathways in platelets and (for ticagrelor) neutrophils, the clinical benefit of these agents is still considered to be to most extent due to their ability to prevent arterial thrombosis.